ChemoCentryx to Present at Two Upcoming Investor Conferences

Rhea-AI Summary

ChemoCentryx, Inc. (Nasdaq: CCXI) has announced presentations by CEO Thomas J. Schall, Ph.D. at upcoming investor conferences. He will speak at the Raymond James 42nd Annual Institutional Investors Conference on March 3 at 2:10 p.m. ET, and at the H.C. Wainwright Global Life Sciences Conference starting March 9 at 7:00 a.m. ET. Webcasts will be available on the company’s website, with replays accessible for two weeks. ChemoCentryx specializes in developing treatments for inflammatory diseases, with its lead drug candidate, avacopan, under FDA review.

MOUNTAIN VIEW, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences:

Raymond James 42nd Annual Institutional Investors Conference
Wednesday, March 3 at 2:10 p.m. Eastern Time

H.C. Wainwright Global Life Sciences Conference
On-demand presentation available beginning Monday, March 9 at 7:00 a.m. Eastern Time

Webcasts of the presentations can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. A replay of each presentation will be available on the Company's website for two weeks following the respective presentation dates.

About ChemoCentryx

ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally administered therapies. ChemoCentryx’s lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late-stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G).

ChemoCentryx also has early-stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.

Contacts:

Susan M. Kanaya                                        
Executive Vice President,                                         
Chief Financial and Administrative Officer
investor@chemocentryx.com                                

Media:
Stephanie Tomei
408.234.1279
media@chemocentryx.com

Investors:
Lee Roth, Burns McClellan
212.213.0006
lroth@burnsmc.com

FAQ

When is the presentation by ChemoCentryx CEO at the Raymond James conference?

The presentation is scheduled for March 3, 2021, at 2:10 p.m. Eastern Time.

Where can I watch the ChemoCentryx investor presentations?

Webcasts of the presentations can be accessed on the Investors section of ChemoCentryx's website.

What is the status of avacopan from ChemoCentryx?

Avacopan is under review by the U.S. Food and Drug Administration following successful completion of a pivotal Phase III trial.

What other conditions is ChemoCentryx developing treatments for?

In addition to ANCA-associated vasculitis, ChemoCentryx is developing avacopan for severe Hidradenitis Suppurativa and C3 glomerulopathy.

What will be covered in the H.C. Wainwright Global Life Sciences Conference presentation?

The on-demand presentation will be available starting March 9, 2021, at 7:00 a.m. Eastern Time.